Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Microbix Biosystems Inc. T.MBX

Alternate Symbol(s):  MBXBF

Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab... see more

TSX:MBX - Post Discussion

Microbix Biosystems Inc. > How many new products does it take…
View:
Post by rjc7 on Jun 13, 2023 8:49am

How many new products does it take…

It seems no matter how many new products they launch, the market just refuses to react. I just don't get it. On the other hand, I suppose developing them, and actually selling the product or two different things. Time will tell. I suppose that's what the market is waiting for. I guess we will have to wait a few more quarters to find out.
Comment by Mbxwatcher on Jun 13, 2023 9:26am
I believe the market needs to see more QAPS deals. I re-read Bruce Krugels last report just the other day.  At this time the consensus seemed to be almost $10 million of VTM sales per year........not zero. The Kinlytic deal, while very good, and exciting is still a few years off before it is material (IMO) The Antigen business is increasing but it is the lowest margin of their business ...more  
Comment by wizzdumb on Jun 13, 2023 6:35pm
They got $2M already and will get $2M more almost certainly before fiscal year end on an asset that was written to zero already. That's right to the bottom line I believe. 
Comment by Mbxwatcher on Jun 13, 2023 10:27pm
Probably not all of it. I imagine the agency they engaged to make the deal gets something.  But I agree it should boost this year's financial results 
Comment by wizzdumb on Jun 13, 2023 6:21pm
Agree. They definitely have no problem with new product development but they need to show the market they can sell a pile of it and make money doing it. Based on Cameron's previous comments they set a high bar on margins but if the volume is zero like with VTM that doesn't help much. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities